Castle Biosciences (CSTL) Environmental, Social & Governance (ESG) Data

On June 2, 2022, Castle Biosciences, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following matters and cast their votes as set forth below:


Proposal 1. Election of Directors


The Company’s stockholders elected the three individuals listed below as Class III Directors, each to serve until the Company’s 2025 annual meeting of stockholders and until their successors are duly elected and qualified. The final voting results are as follows:



Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm


The Company’s stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company’s Board of Directors (the “Board”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:





Proposal 3. Approval of the Compensation of the Company’s Executive Officers


The Company’s stockholders did not approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The final voting results are as follows:





Proposal 4. Approval of the Frequency of the Say-on-Pay Vote


The Company’s stockholders indicated, on an advisory basis, the preferred frequency of one year for future stockholder advisory votes on the compensation of the Company’s named executive officers. In light of this result and consistent with the Company’s recommendation, the Board has determined to hold future advisory votes on executive compensation every year. Under Section 14a-21(b) of the Securities Exchange Act of 1934, as amended, the Company will hold the next advisory vote on the frequency of such stockholder votes no later than its 2028 annual meeting of stockholders. The final voting results are as follows: